Abstract
Breast cancer is a heterogeneous disease and patients are managed clinically based
on ER, PR, HER2 expression, and key risk factors. The use of gene expression assays
for early stage disease is already common practice. These tests have found a place
in risk stratifying the heterogeneous group of stage I–II breast cancers for recurrence,
for predicting chemotherapy response, and for predicting breast cancer-related mortality.
Most guidelines for hormone receptor (HR)–positive early breast cancer recommend addition
of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable
morbidity and cost. Expert oncologist discussed about strategies of gene expression
assays and aid in chemotherapy recommendations for treatment of HR + ve EBC and the
expert group used data from published literature, practical experience and opinion
of a large group of academic oncologists to arrive at this practical consensus recommendations
for the benefit of community oncologists.
Key words
ki67 - mammaprint - oncotype dx - predictive test - prosigna - taxane
